title: Glycosaminoglycans from two human malignant mesothelioma cell lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis.
abstract: The synthesis and distribution of glycosaminoglycans (GAGs) were studied in two human malignant mesothelioma cell lines: one with fibroblast-like morphology and the other with epithelial differentiation. Analyses using highly sensitive high-pressure liquid chromatography techniques and agarose gel electrophoresis showed that these cells produce not only hyaluronan (HA) but also galactosaminoglycans (GalAGs, chondroitin sulfate and (or) dermatan sulfate) and heparan sulfate (HS). In both cell lines most of the HA (87-90%) and GalAGs (57-66%) are secreted into the extracellular matrix. Although HS is mainly bound to the cell surface in fibroblast-differentiated cells (75%), in epithelial type cells only 40% occurs in the cell-associated fraction. The amounts of secreted GAGs are 6- to 8-fold higher in epithelial than in fibroblast-like mesothelioma cultures. In cells with the fibroblast phenotype, the beta-homodimer of platelet-derived growth factor (PDGF) in a concentration of 1.5 ng/mL stimulates HA and GalAG synthesis 5-fold and that of HS 10-fold, whereas higher concentrations suppress this stimulatory effect. The stimulatory effect, observed at low concentrations of this growth factor, was completely blocked by the addition of antibodies against this factor. In epithelially differentiated cells, the production of all GAGs was suppressed after addition of this factor, even at low concentrations. We therefore suggest that mesothelioma cells can produce GAGs, the synthesis of which is dependent on the presence and concentration of PDGF beta-homodimer. The differences between the two cell lines regarding the effect of this growth factor on GAG synthesis indicates that the regulation of this synthesis is complex, other factors also being important.
authors.affiliation: Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Sweden.
authors.forename: G N
authors.initials: GN
authors.lastname: Tzanakakis
authors.forename: N K
authors.initials: NK
authors.lastname: Karamanos
authors.forename: J
authors.initials: J
authors.lastname: Klominek
authors.forename: A
authors.initials: A
authors.lastname: Hjerpe
mesh_terms: D000077214:Becaplermin; D002454:Cell Differentiation; D004847:Epithelial Cells; D005109:Extracellular Matrix / Q000737:chemistry; D005347:Fibroblasts / Q000166:cytology; D006025:Glycosaminoglycans / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D008654:Mesothelioma / Q000737:chemistry / Q000378:metabolism*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D010997:Pleural Neoplasms / Q000737:chemistry / Q000378:metabolism*; D020574:Proto-Oncogene Proteins c-sis; D014407:Tumor Cells, Cultured
chemical_list: D006025:Glycosaminoglycans; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin